First Trust Direct Indexing L.P. Purchases Shares of 829 Bio-Rad Laboratories, Inc. (NYSE:BIO)

First Trust Direct Indexing L.P. acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 829 shares of the medical research company’s stock, valued at approximately $277,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Capital Advisors Ltd. LLC raised its stake in Bio-Rad Laboratories by 193.8% during the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 62 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Bio-Rad Laboratories by 140.6% in the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. EntryPoint Capital LLC purchased a new position in Bio-Rad Laboratories in the first quarter worth about $51,000. Headlands Technologies LLC bought a new stake in Bio-Rad Laboratories during the second quarter worth approximately $51,000. Finally, Quarry LP bought a new stake in shares of Bio-Rad Laboratories in the 2nd quarter valued at approximately $59,000. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Trading Up 0.1 %

NYSE BIO opened at $368.92 on Tuesday. Bio-Rad Laboratories, Inc. has a 12 month low of $262.12 and a 12 month high of $372.27. The company’s 50-day moving average price is $333.99 and its 200-day moving average price is $308.71. The stock has a market cap of $10.28 billion, a PE ratio of -13.50 and a beta of 0.93. The company has a current ratio of 6.14, a quick ratio of 4.63 and a debt-to-equity ratio of 0.16.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.85. The firm had revenue of $649.70 million during the quarter, compared to analyst estimates of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. Bio-Rad Laboratories’s quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.33 earnings per share. Equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 9.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on BIO shares. Royal Bank of Canada increased their price target on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday. Citigroup upped their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $391.80.

Insider Activity

In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares in the company, valued at $48,582.03. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the sale, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the transaction, the executive vice president now owns 147 shares in the company, valued at $48,582.03. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.